SEC FORM
3
SEC Form 3
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
|
| OMB APPROVAL |
| OMB Number: |
3235-0104 |
| Estimated average burden |
| hours per response: |
0.5 |
|
|
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year)
06/02/2014
|
3. Issuer Name and Ticker or Trading Symbol
AbbVie Inc.
[ ABBV ]
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
Director |
|
10% Owner |
| X |
Officer (give title below) |
|
Other (specify below) |
|
EVP, R&D and CSO
|
|
5. If Amendment, Date of Original Filed
(Month/Day/Year)
|
6. Individual or Joint/Group Filing (Check Applicable Line)
| X |
Form filed by One Reporting Person |
|
Form filed by More than One Reporting Person |
|
| Table I - Non-Derivative Securities Beneficially Owned |
|---|
| 1. Title of Security (Instr.
4)
|
2.
Amount of Securities Beneficially Owned (Instr.
4)
|
3. Ownership Form: Direct (D) or Indirect (I) (Instr.
5)
|
4. Nature of Indirect Beneficial Ownership (Instr.
5)
|
| Common stock, $0.01 par value |
0 |
D |
|
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
|
|---|
| 1. Title of Derivative Security (Instr.
4)
|
2. Date Exercisable and Expiration Date
(Month/Day/Year) |
3. Title and Amount of Securities Underlying Derivative Security (Instr.
4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form: Direct (D) or Indirect (I) (Instr.
5)
|
6. Nature of Indirect Beneficial Ownership (Instr.
5)
|
| Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
| Explanation of Responses: |
|
Steven L. Scrogham, attorney-in-fact for Michael Severino |
06/04/2014 |
|
** Signature of Reporting Person |
Date |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
| * If the form is filed by more than one reporting person,
see
Instruction
5
(b)(v). |
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure. |
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |
Exhibit 24.1
POWER OF ATTORNEY
The undersigned constitutes and appoints LAURA J. SCHUMACHER, KATHLEEN
M.S. SCHEIDT, JENNIFER M. LAGUNAS and STEVEN L. SCROGHAM, and each of
them individually, as the undersigned's true and lawful attorney-in-fact
and agent, with full power of substitution and re-substitution, for the
undersigned and in the undersigned's name, place and stead, to prepare
and sign any and all Securities and Exchange Commission("SEC") Notices
of Proposed Sales of Securities pursuant to Rule 144 under the
Securities Act of 1933 on Form 144, all SEC statements on Forms 3, 4
and 5 as required under Section 16(a) of the Securities Exchange Act
of 1934, including a Form ID and any other documents necessary to
obtain codes and passwords necessary to make electronic filings, and
any amendments to such forms, and to file the same with all exhibits
thereto, and other documents in connection therewith, with the SEC,
granting unto said attorney-in-fact and agent full power and authority
to do and perform each act and thing requisite, necessary or desirable
to be done under said Rule 144 and Section 16(a), as fully for all
intents and purposes as the undersigned might or could do in person,
hereby ratifying and confirming all that said attorney-in-fact and agent
may lawfully do or cause to be done by virtue hereof.
A copy of this power of attorney shall be filed with the SEC. The
authorization set forth above shall continue in full force and effect
until the undersigned is no longer required to file Forms 144, 3, 4, or
5 or if earlier, until the undersigned revokes such authorization by
written instructions to the attorney-in-fact.
Date: May 26, 2014
/s/ Michael Severino
Signature of Reporting Person
Michael Severino, M.D.
AbbVie Inc.
1 N. Waukegan Road
North Chicago, IL 60064
